Physician profile
Youngjun Park
NPI 1275971004
$764.80
in general payments reported to CMS, 2019-2025
16 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $15.19 · 2021: $38.50 · 2022: $143 · 2023: $152 · 2024: $156 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $74.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.28 |
| Education | $74.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.52 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $87.65 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $85.01 | 2022-2023 | Tarpeyo |
| E.R. Squibb & Sons, L.L.C. | $80.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $77.79 | 2021-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $58.82 | 2021-2025 | Veltassa |
| Akebia Therapeutics INC | $49.28 | 2024-2025 | Vafseo |
| Janssen Pharmaceuticals, INC | $44.33 | 2019 | |
| Mallinckrodt Hospital Products INC. | $42.90 | 2022-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $31.04 | 2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.43 | 2023 | |
| Glaxosmithkline, LLC. | $21.41 | 2023 | Jesduvroq |
| Novo Nordisk INC | $20.90 | 2024 | Rivfloza |
| Amgen INC. | $19.28 | 2025 | Tavneos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youngjun Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.